the effects of fenofibrate on lipids , lipoproteins , and apolipoproteins in 33 subjects with primary hypercholesterolemia were assessed in a 6-month parallel group study , placebo ( n = 15 ) versus fenofibrate 300 mg/day ( n = 18 ) , followed by an open label 6-month treatment period .
C0023779
lipids
C0023820
lipoproteins